BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33878964)

  • 1. Single Center Experience of Sirolimus Therapy in Head and Neck Low-flow Vascular Malformations.
    Pang C; Evans N; Jethwa P; Papadopoulou A; Khalifa M; Tsui J; Hamilton G; Lim CS; Brookes J
    Vasc Endovascular Surg; 2021 Jul; 55(5):482-490. PubMed ID: 33878964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
    Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
    Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.
    Hammer J; Seront E; Duez S; Dupont S; Van Damme A; Schmitz S; Hoyoux C; Chopinet C; Clapuyt P; Hammer F; Vikkula M; Boon LM
    Orphanet J Rare Dis; 2018 Oct; 13(1):191. PubMed ID: 30373605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of sirolimus in children with lymphatic malformations of the head and neck.
    Wiegand S; Dietz A; Wichmann G
    Eur Arch Otorhinolaryngol; 2022 Aug; 279(8):3801-3810. PubMed ID: 35526176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral sirolimus for high-flow vascular malformations in real clinical practice.
    Durán-Romero AJ; Hernández-Rodríguez JC; Ortiz-Álvarez J; Domínguez-Cruz JJ; Monserrat-García MT; Conejo-Mir Sánchez J; Bernabeu-Wittel J
    Clin Exp Dermatol; 2022 Jan; 47(1):57-62. PubMed ID: 34240451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with Congenital Low-Flow Vascular Malformation Treated with Low Dose Sirolimus.
    Harbers VEM; Rongen GAPJM; van der Vleuten CJM; Verhoeven BH; de Laat PCJ; van der Horst CMAM; Klein WM; Schultze Kool LJ; Loo DMWMT
    Adv Ther; 2021 Jun; 38(6):3465-3482. PubMed ID: 34003452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations.
    Geeurickx M; Labarque V
    J Vasc Surg Venous Lymphat Disord; 2021 Sep; 9(5):1321-1333. PubMed ID: 33737259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective multicenter study of sirolimus for complicated vascular anomalies.
    Ji Y; Chen S; Yang K; Zhou J; Zhang X; Jiang X; Xu X; Lu G; Qiu L; Kong F; Zhang Y
    J Vasc Surg; 2021 Nov; 74(5):1673-1681.e3. PubMed ID: 34082006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
    Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
    Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children: A single-center experience.
    Cho YJ; Kwon H; Kwon YJ; Kim SC; Kim DY; Namgoong JM
    J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1488-1494. PubMed ID: 33836285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
    Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
    JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Data on the Use of Sirolimus in Asian Children with Vascular Malformations.
    Yu L; Xu Z; Wei L; Zhang B; Qiu L; Ma L; Li L
    Paediatr Drugs; 2024 May; 26(3):309-317. PubMed ID: 38280106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of major complications from embolo-sclerotherapy of head and neck vascular malformations in a single specialist centre.
    Smith H; Lim CS; Evans N; Papadopoulou A; Khalifa M; Tsui J; Hamilton G; Brookes J
    Vascular; 2022 Oct; 30(5):952-959. PubMed ID: 34311627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus treatment for paediatric head and neck lymphatic malformations: a systematic review.
    Saibene AM; Rosso C; Felisati G; Pignataro L; Schindler A; Ghilardi G; Colletti G; Gaffuri M; Mozzanica F
    Eur Arch Otorhinolaryngol; 2023 Aug; 280(8):3529-3540. PubMed ID: 37115326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sirolimus in the treatment of vascular malformations: A protocol for systematic review and meta-analysis.
    Dong J; Han D; Wang D; Lu H; Wang X
    Medicine (Baltimore); 2020 Oct; 99(40):e22596. PubMed ID: 33019479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnitude and relevance of change in health-related quality of life in patients with vascular malformations treated with sirolimus.
    Harbers VEM; Bouwman FCM; van Rijnsoever IMP; Verhoeven BH; van der Vleuten CJM; Schultze Kool LJ; de Laat PCJ; van der Horst CMAM; Kievit W; Te Loo DMWM
    Front Med (Lausanne); 2023; 10():1155476. PubMed ID: 37153086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early follow-up quality of life and mental health of patients with congenital vascular malformations cared for in a multi-disciplinary specialist centre.
    Pang C; Nisbet R; Gibson M; Evans N; Khalifa M; Papadopoulou A; Tsui J; Hamilton G; Brookes J; Lim CS
    Phlebology; 2023 Mar; 38(2):80-90. PubMed ID: 36541140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sirolimus on coagulopathy of slow-flow vascular malformations.
    Mack JM; Verkamp B; Richter GT; Nicholas R; Stewart K; Crary SE
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27896. PubMed ID: 31250546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Our experience with sirolimus for the treatment of complicated vascular anomalies].
    Giménez-Aleixandre C; Méndez-Aguirre NA; Martínez-Menchón T; Girón Vallejo Ó; Fernández-Ibieta M; Ferri-Ñíguez B; Villamil V; Sánchez-Sánchez Á; Montoya-Rangel CA; Hernández-Bermejo JP
    Cir Pediatr; 2019 Jan; 32(1):28-33. PubMed ID: 30714698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of foam sclerotherapy for treatment of low-flow vascular malformations in children.
    Markovic JN; Nag U; Shortell CK
    J Vasc Surg Venous Lymphat Disord; 2020 Nov; 8(6):1074-1082. PubMed ID: 32284312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.